Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2014', provides an overview of the Beijing Minhai Biotechnology Co., Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Beijing Minhai Biotechnology Co., Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Beijing Minhai Biotechnology Co., Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Beijing Minhai Biotechnology Co., Ltd's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Beijing Minhai Biotechnology Co., Ltd's pipeline products

Reasons to buy

- Evaluate Beijing Minhai Biotechnology Co., Ltd's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Beijing Minhai Biotechnology Co., Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Beijing Minhai Biotechnology Co., Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Beijing Minhai Biotechnology Co., Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Beijing Minhai Biotechnology Co., Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Beijing Minhai Biotechnology Co., Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Beijing Minhai Biotechnology Co., Ltd Snapshot 6
Beijing Minhai Biotechnology Co., Ltd Overview 6
Key Information 6
Key Facts 6
Beijing Minhai Biotechnology Co., Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
Beijing Minhai Biotechnology Co., Ltd - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Beijing Minhai Biotechnology Co., Ltd - Pipeline Products Glance 15
Beijing Minhai Biotechnology Co., Ltd - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Beijing Minhai Biotechnology Co., Ltd - Clinical Stage Pipeline Products 17
Phase I Products/Combination Treatment Modalities 17
Beijing Minhai Biotechnology Co., Ltd - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Beijing Minhai Biotechnology Co., Ltd - Drug Profiles 19
pneumococcal polysaccharide vaccine (23-valent) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
hepatitis A vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
hepatitis B vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
meningococcal conjugate vaccine [serogroups A, C, Y and W135] 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
cholera vaccine (trivalent) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
diphtheria + tetanus + pertussis (acellular) vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
haemophilus influenzae conjugate vaccine [type B] 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
hepatitis A + hepatitis B vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
influenza vaccine (split virion) 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
meningococcal conjugate vaccine (tetravalent) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
meningococcal polysaccharide vaccine (tetravalent) 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
pneumococcal conjugate vaccine [13-valent] 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
rabies vaccine [MRC-5] 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
enterovirus 71 vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
herpes vaccine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
human papillomavirus vaccine (tetravalent) 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
influenza vaccine [H1N1] 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
meningococcal vaccine [serogroup B] 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
pneumococcal conjugate vaccine (15-valent) 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rotavirus vaccine (pentavalent) 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Beijing Minhai Biotechnology Co., Ltd - Pipeline Analysis 39
Beijing Minhai Biotechnology Co., Ltd - Pipeline Products by Route of Administration 39
Beijing Minhai Biotechnology Co., Ltd - Pipeline Products by Molecule Type 40
Beijing Minhai Biotechnology Co., Ltd - Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Beijing Minhai Biotechnology Co., Ltd, Key Information 6
Beijing Minhai Biotechnology Co., Ltd, Key Facts 6
Beijing Minhai Biotechnology Co., Ltd - Pipeline by Indication, 2014 9
Beijing Minhai Biotechnology Co., Ltd - Pipeline by Stage of Development, 2014 10
Beijing Minhai Biotechnology Co., Ltd - Monotherapy Products in Pipeline, 2014 11
Beijing Minhai Biotechnology Co., Ltd - Combination Treatment Modalities in Pipeline, 2014 12
Beijing Minhai Biotechnology Co., Ltd - Partnered Products in Pipeline, 2014 13
Beijing Minhai Biotechnology Co., Ltd - Partnered Products/ Combination Treatment Modalities, 2014 14
Beijing Minhai Biotechnology Co., Ltd - Pre-Registration, 2014 15
Beijing Minhai Biotechnology Co., Ltd - Phase III, 2014 16
Beijing Minhai Biotechnology Co., Ltd - Phase I, 2014 17
Beijing Minhai Biotechnology Co., Ltd - Preclinical, 2014 18
Beijing Minhai Biotechnology Co., Ltd - Pipeline by Route of Administration, 2014 39
Beijing Minhai Biotechnology Co., Ltd - Pipeline by Molecule Type, 2014 40